Mavi Akrep Zehiri (Rhopalurus Junceus)
Özet
Tamamlayıcı veya alternatif tedaviler toplumda nerdeyse her hastalık için yaygın olarak kullanılan çoğunluğu geleneksel olan tedavilerdir. Bunların önemli bir kısmının bilimsel altyapısı yoktur. Sık kullanılan ajanlardan birisi olan Rhopalurus Junceus(Mavi akrep zehiri) kuba bulunan bir akrepten elde edilen zehirdir ve kanser hastalarında sık kullanılmaktadır. Zehirin iyon kanllarını etki ederek ve apopitozu düzenleyerek etki ettiği düşünülmektedir. Yapılan hücre ve hayvan çalışmalarının bir kısmında kanser hücreleri üzerine sitotoksik etkisi görülmüş olsa da insanlar üzerinde yapılan klinik çalışma bulunmamaktadır. Yine hayvan deneylerinden elde edilen bilgiler yan etkilerinin ciddi olmadığını göstermekle beraber literature de ölüme neden olan bir vaka bildirilmiştir. Bu gün ki bilimsel veriler ışığında kanser hastalarına önerilecek düzeyde kanıt bulunmamaktadır.
Complementary or alternative therapies are traditional treatments widely used in society for various diseases. However, many of these therapies lack scientific evidence. Rhopalurus Junceus, commonly known as blue scorpion venom, is one such agent that is frequently used in cancer patients. The venom is believed to affect ion channels and regulate apoptosis. While some cell and animal studies have demonstrated cytotoxic effects on cancer cells, there have been no clinical studies conducted on humans. Additionally, although information obtained from animal experiments suggests that the side effects are not severe, there has been a reported case of death in the literature. Based on current scientific data, there is insufficient evidence to recommend this treatment to cancer patients.
Referanslar
Balneaves L. G., Bottorff J. L., Hislop T. G. & Herbert C. Levels of commitment: exploring complementary therapy use by women with breast cancer. J. Altern. Complement. Med. 12, 459–466 (2006).
John G. M. et al. Complementary and alternative medicine use among US cancer survivors. J. Cancer Surviv. 10, 850–64 (2016)
Cao J, Rivera F, Bello F. IV Simposio de Zoologia. Habana- Cuba: Livro de Resumenes; 1997. Algunos aspectos bioecologicos y farmacológicos del veneno crudo procedente de dos especies de escorpiones cubanos; p. p. 70
Díaz-García A, Ruiz-Fuentes JL, Yglesias-Rivera A. Enzymatic analysis of venom from Cuban scorpion Rhopalurus junceus. J Venom Res. 2015;6:11–18
Gomes A. et al. Anticancer potential of animal venoms and toxins. Indian. J. Exp. Biol. 48, 93–103 (2010)
Diaz-Garcia A. et al. In vitro anticancer effect of venom from Cuban scorpion Rhopalurus junceus against a panel of human cancer cell lines. J. Venom Res. 4, 5–12 (2013)
Rodríguez-Ravelo R, Batista CV, Coronas FI, Zamudio FZ, Hernández-Orihuela L, Espinosa-López G, Ruiz-Urquiola A, Possani LD. Comparative proteomic analysis of male and female venoms from the Cuban scorpion Rhopalurus junceus. Toxicon. 2015 Dec 1;107(Pt B):327-34. doi: 10.1016/j.toxicon.2015.06.026. Epub 2015 Jul 10. PMID: 26169670.
Rodríguez-Ravelo R, Coronas FI, Zamudio FZ, González-Morales L, López GE, Urquiola AR, Possani LD. The Cuban scorpion Rhopalurus junceus (Scorpiones, Buthidae): component variations in venom samples collected in different geographical areas. J Venom Anim Toxins Incl Trop Dis. 2013 May 20;19(1):13. doi: 10.1186/1678-9199-19-13. PMID: 23849540; PMCID: PMC3710086.
Ortiz E, Gurrola G, Schwartz E, Possani L. Scorpion venom components as potential candidates for drug development. Toxicon. 2015;93:125–135. , Hmed B, Serria H, Mounir Z. Scorpion peptides: potential use for new drug development. J Toxicol. 2013;2013:958797.33
Catterall W, Cestèle S, Yarov-Yarovoy V, Yu F, Konoki K, Scheuer T. Voltage-gated ion channels and gating modifier toxins. Toxicon. 2007;49:124–141
García-Gómez BI, Coronas FI, Restano-Cassulini R, Rodríguez RR, Possani LD. Biochemical and molecular characterization of the venom from the Cuban scorpion Rhopalurus junceus. Toxicon. 2011 Jul;58(1):18-27. doi: 10.1016/j.toxicon.2011.04.011. Epub 2011 May 13. PMID: 21605585
Díaz-García A, Ruiz-Fuentes JL, Frión-Herrera Y, Yglesias-Rivera A, Garlobo YR, Sánchez HR, Aurrecochea JCR, López Fuentes LX. Rhopalurus junceus scorpion venom induces antitumor effect in vitro and in vivo against a murine mammary adenocarcinoma model. Iran J Basic Med Sci. 2019 Jul;22(7):759-765. doi: 10.22038/ijbms.2019.33308.7956. PMID: 32373297; PMCID: PMC7196348.
Díaz-García A, Ruiz-Fuentes JL, Rodríguez-Sánchez H, Fraga Castro JA. Rhopalurus junceus scorpion venom induces apoptosis in the triple negative human breast cancer cell line MDA-MB-231. J Venom Res. 2017 Apr 16;8:9-13. PMID: 29285349; PMCID: PMC5735679
Lozano-Trujillo LA, Garzón-Perdomo DK, Vargas ACR, de Los Reyes LM, Avila-Rodriguez MF, Gay OTG, Turner LF. Cytotoxic Effects of Blue Scorpion Venom (Rhopalurus junceus) in a Glioblastoma Cell Line Model. Curr Pharm Biotechnol. 2021;22(5):636-645. doi: 10.2174/1389201021666200717092207. PMID: 32679017.
Giovannini C, Baglioni M, Baron Toaldo M, Cescon M, Bolondi L, Gramantieri L. Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. Sci Rep. 2017 Mar 21;7:44685. doi: 10.1038/srep44685. Erratum in: Sci Rep. 2017 Dec 22;7:46920. PMID: 28322221; PMCID: PMC5359575
Lagarto A, Bueno V, Pérez MR, Rodríguez CC, Guevara I, Valdés O, Bellma A, Gabilondo T, Padrón AS. Safety evaluation of the venom from scorpion Rhopalurus junceus: Assessment of oral short term, subchronic toxicity and teratogenic effect. Toxicon. 2020 Mar;176:59-66. doi: 10.1016/j.toxicon.2020.02.002. Epub 2020 Feb 11. PMID: 32057833.
Yglesias-Rivera, A.; Rodríguez-Sánchez, H.; Díaz-García, A. Synergistic effect of Rhopalurus junceus scorpion venom combined with conventional cytostatics in cervical cancer cell line HeLa. J. Pharm. Pharmacogn. Res. 2019, 7, 67–76.
Damadoğlu E, Irmak İ, Kalyoncu AF. Cuban Blue Scorpion Venom and Lung Carcinoma: Is it Always True What Does Not Kill Me Makes Me Stronger? Turk Thorac J. 2021 May;22(3):265-266. doi: 10.5152/TurkThoracJ.2021.20202. PMID: 35110239; PMCID: PMC8975375.
http://vidatoxromania.ro/en/what-is-vidatox/) (http://www.bt.com.bn/science-technology/2010/10/29/cuba-release-new-cancer-drug
Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst. 2018;110(1):121–124.. 10.1093/jnci/djx145
Angell M, Kassirer JP. Alternative medicine-the risks of untested and unregulated remedies. N Engl J Med. 1998;339:839–840.
Chang EY, Glissmeyer M, Tonnes S, et al. Outcomes of breast cancer in patients who use alternative therapies as primary treatment. Am J Surg. 2006; 192(4):471–473.
Coppes MJ, Anderson RA, Egeler RM, et al. Alternative therapies for the treatment of childhood cancer. N Engl J Med. 1998;339(12):846–847. 25. Ernst E. Intangible risks of complementary and alternative medicine. J Clin Oncol. 2001;19(8):2365–2366.
Han E, Johnson N, DelaMelena T, et al. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol. 2011;18(4):912–916.
Joseph K, Vrouwe S, Kamruzzaman A, et al. Outcome analysis of breast cancer patients who declined evidence-based treatment. World J Surg Oncol. 2012; 10(1):1. 7. Saquib J, Parker BA, Natarajan L, et al. Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer. Complement Ther Med. 2012;20(5):283–290
